Medical Use
Ukoniq is a kinase inhibitor used to treat adult patients with:
- Relapsed or refractory marginal zone lymphoma (MZL) who have previously received at least one anti-CD20-based regimen.
- Relapsed or refractory follicular lymphoma (FL) who have previously received at least three lines of systemic therapy.
Recommended Dosage: The recommended dose is 800 mg taken orally once daily with food, continuing until disease progression or unacceptable toxicity occurs. Swallow the tablets whole without chewing, crushing, breaking, or cutting them. Ukoniq should be taken consistently each day. If vomiting occurs, do not take an additional dose; simply continue with the next scheduled dose. If a dose is missed, take it unless it is less than twelve hours until the next scheduled dose.
Warning & Precautions
Severe and potentially fatal infections have been reported in patients treated with Umbralisib. Monitor for any new or worsening signs of infection. For Grade 3 or 4 infections, withhold Umbralisib until the infection resolves.
Pneumocystis jirovecii pneumonia (PJP) prophylaxis is recommended during Umbralisib therapy. Withhold treatment in patients with suspected PJP of any grade and permanently discontinue in confirmed cases.
Cytomegalovirus (CMV) infection should be monitored in patients with a history of CMV while on Umbralisib. Consider prophylactic antivirals to prevent CMV infection or reactivation.
Severe neutropenia has been observed in patients treated with Umbralisib. Monitor neutrophil counts every two weeks for the first two months and weekly in patients with counts <1 × 10^9/L (Grade 3-4). Provide supportive care as needed.
Serious diarrhea or non-infectious colitis can occur with Umbralisib. For severe diarrhea (Grade 3, i.e., more than 6 stools daily over baseline) or symptoms like mucus or blood in stool, abdominal pain, or changes in bowel habits, withhold treatment until resolved and provide supportive care with antidiarrheals or enteric-acting steroids.
Serious hepatotoxicity has been reported with Umbralisib. Monitor liver function during treatment. For ALT/AST levels 5 to less than 20 times the upper limit of normal (ULN), withhold therapy until levels return to less than three times ULN, then resume at a reduced dose.
Serious cutaneous reactions, including fatal cases of exfoliative dermatitis, have been observed. Assess patients for new or worsening skin reactions. Review all concomitant medications and interrupt any that may contribute. Evaluate weekly until resolved.
Fetal harm can occur if Umbralisib is administered to a pregnant woman. Females of reproductive age and males with female partners of reproductive age should use effective contraception during treatment and for 30 days after the final dose.
Documentation Availability
Documents required to import UKONIQ to India?
UKONIQ (umbralisib) tablets can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing UKONIQ (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Ukoniq®?
The generic name for Ukoniq® is umbralisib.
Who manufactures Ukoniq®?
Ukoniq® is manufactured by TG Therapeutics, Inc.
Is Ukoniq® FDA approved?
Yes, Ukoniq® was approved by the FDA on February 5, 2021.
What is Ukoniq®?
Ukoniq, also known as umbralisib tosylate, is a kinase inhibitor used to treat adult patients with relapsed or refractory marginal zone lymphoma (MZL) or follicular lymphoma (FL) after other anticancer therapies have failed.
What is the dosage form of Ukoniq®?
Ukoniq® is available as 200 mg tablets for oral administration.
What are the common side effects of Ukoniq®?
Common side effects include rash, fatigue, nausea, neutropenia, elevated transaminase levels, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, and decreased appetite.
How much does Ukoniq® cost in India?
Ukoniq® is reasonably priced in India. For authentic procurement, you can reach out to Rx4u team.
What are the storage conditions for Ukoniq®?
Store Ukoniq® tablets at 68°F to 77°F (20°C to 25°C). Temperature excursions between 59°F and 86°F (15°C to 30°C) are permitted.
Is it safe to buy Ukoniq® online in India?
Yes, you can safely purchase Ukoniq® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information
